-
Dec 30, 2024 | 
bmj.com | William B. Feldman |Samy Suissa |Aaron S. Kesselheim |Jerry Avorn
Research BMJ 2024; 387 doi: https://doi.org/10.1136/bmj-2024-080409 Cite this as: BMJ 2024;387:e080409 Linked Editorial Environmentally friendly inhaler regimens for COPD William B Feldman, assistant professor1 2 3, Samy Suissa, professor4, Aaron S Kesselheim, professor1 3, Jerry Avorn, professor1 3, Massimiliano Russo, assistant professor5, Sebastian Schneeweiss, professor1 3, Shirley V Wang, associate professor1 3 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of...
-
Nov 25, 2024 | 
jamanetwork.com | Olivier J. Wouters |Matthew Vogel |William B. Feldman |Aaron S. Kesselheim
Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US Abstract Importance Biologics approved by the US Food and Drug Administration (FDA) receive 12 years of guaranteed protection from biosimilar competition compared with 5 years of protection from generic competition for new small-molecule drugs.
-
Oct 21, 2024 | 
jamanetwork.com | Hussain Lalani |Catherine Hwang |Aaron S. Kesselheim
Abstract
Importance
In the US, many patients struggle to afford prescription drugs, leading to adverse health outcomes. To improve cost-related medication nonadherence, prescribers and clinical staff must understand how to assist patients in overcoming high prescription drug costs.
-
Oct 7, 2024 | 
jamanetwork.com | Thomas Hwang |Aaron S. Kesselheim
Clinical trials of new drugs historically excluded children.
-
Sep 23, 2024 | 
jamanetwork.com | Christopher Cai |Aaron S. Kesselheim
In 2023, the Center for Medicare & Medicaid Innovation Center proposed the Medicare High-Value Drug List Model (hereafter, the model), in which Medicare Part D plans would voluntarily cap out-of-pocket costs at $2 per month for 150 high-value generic medications.1,2 We estimated potential savings from this policy.
-
Sep 18, 2024 | 
jamanetwork.com | Aaron S. Kesselheim |William B. Feldman |Arash Mostaghimi |BSc Hons
Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa—Reply Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa Adam J. N. Raymakers, PhD; Aaron S. Kesselheim, MD, JD, MPH; Arash Mostaghimi, MD, MPA, MPH; William B. Feldman, MD, DPhil, MPH Estimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa Michelle K. Y.
-
Sep 17, 2024 | 
onlinelibrary.wiley.com | Kevin A. Schulman |Aaron S. Kesselheim |William B. Feldman |Iselin Dahlen Syversen
Policy Points Health care systems around the world rely on a range of methods to ensure the affordability of prescription drugs, including negotiating prices soon after drug approval and relying on formal clinical assessments that compare newly approved therapies with existing alternatives. The negotiation framework established under the Inflation Reduction Act is far more limited than other frameworks explored in this study.
-
Sep 5, 2024 | 
jamanetwork.com | Liam Bendicksen |Aaron S. Kesselheim |William B. Feldman
Seeking a Better Paper Trail of Federal Research Funding The US federal government invests billions of dollars annually in pharmaceutical research and development.
-
Aug 26, 2024 | 
jamanetwork.com | Aaron S. Kesselheim
When a patient is prescribed an expensive drug, a patient assistance program can help cover the cost. Funded primarily by drug manufacturers, even when they are nominally independent charitable organizations, patient assistance programs generally apply to patients with insurance and primarily cover expensive brand-name and specialty drugs.
-
Aug 2, 2024 | 
healthaffairs.org | Daniel Klein |Aaron S. Kesselheim
In June 2024, a Food and Drug Administration (FDA) advisory committee held a hearing to review the evidence for approving a version of midomafetamine (MDMA) therapy, a psychedelic, in combination with psychotherapy to treat post-traumatic stress disorder (PTSD).
